• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Beneficial effect of intensive blood pressure control on cardiovascular and all-cause mortality not persist after trial intervention – a secondary analysis of the SPRINT trial

byGursharan SohiandYuchen Dai
October 17, 2022
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Intensive blood pressure control regime was associated with improved cardiovascular and all-cause mortality at a median follow-up point of 3.3 years.

2. After a median of 8.8 years, there was no significant improvement in mortality rates between patients who had undergone intensivist versus consistent blood pressure control.

Level of Evidence Rating: 1 (Excellent)

Study Rundown: Essential hypertension is a common risk factor for cardiovascular disease and associated mortality. Fortunately, it is modifiable, and high-quality studies have shown that pharmacological blood pressure control interventions can effectively reduce cardiovascular and all-cause mortality associated with high blood pressure. Recent trials demonstrated that mortality was lowered with intensive antihypertensive treatment although their follow-up duration was limited. The present study sought to determine whether the mortality benefits of intensive antihypertensive control persist long-term in comparison to standard, consistent blood pressure control strategies.

9361 participants were randomized in total to the intensive or consistent blood pressure control groups with 120 mmHg or 140 mmHg targets, respectively. The total median follow-up time was 8.8 years in both groups. There was a mortality benefit to intensive treatment compared to consistent treatment during the trial phase (less than 3 years follow-up) but not at the trial endpoint. This trend was true for both cardiovascular mortality as well as all-cause mortality. The benefit of intensive blood pressure control from a cardiovascular mortality standpoint extended from 2.3 to 5.6 years of follow-up, after which point it was not significantly better than consistent blood pressure control.

The present study concluded that intensive blood pressure control to a target systolic blood pressure of 120 mmHg is beneficial in lowering mortality risk in the short term compared to consistent blood pressure control at a higher target (140 mmHg), but that this effect is not persistent beyond approximately 5 years. A major strength of this study is the large sample size and long-term follow-up period. However, this work has limited external validity as the trial population was highly selected to exclude many common comorbidities.

Click here to read this study in JAMA Cardiology

RELATED REPORTS

Socioeconomic status may influence the association between physical activity and health outcomes

Wellness Check: Exercise

Ultrasound renal denervation associated with reduced blood pressure in the RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials – A pooled analysis

Click to read an accompanying editorial in JAMA Cardiology

Relevant reading: A randomized trial of intensive versus standard blood pressure control

In-Depth [randomized controlled trial]: A multi-center randomized controlled trial was performed. Eligible participants were aged 50 or greater and had an index blood pressure measurement of between 130-180 mmHg. High-risk features included cardiovascular disease, chronic kidney disease, or a Framingham risk score greater than 14% if above age 75. Patients with a history of dementia, diabetes, stroke, polycystic kidney disease or proteinuria were excluded, as were residents of nursing homes. Patients were randomized in a 1:1 ratio to undergo antihypertensive treatment targeting a systolic blood pressure of either 120 mmHg (intensive group) or 140 mmHg (consistent group) over a 5-year period. Standardized equipment and procedures were used to measure blood pressure across study sites.

A total of 818 (intensive group) and 826 (consistent group) deaths occurred amongst trial participants during the study period due to any cause. The hazard ratio for all-cause mortality in the intensive versus consistent groups was 0.83 (95% confidence interval 0.68-1.01) during the first three years of the trial and 1.08 (95% confidence interval 0.94-1.23) thereafter. At the trial endpoint, the total number of deaths from cardiovascular causes was 248 in the intensive group and 273 in the consistent group. The hazard ratio for cardiovascular mortality was 0.66 (0.49-0.89) during the trial phase and 1.02 (0.84-1.24) at the trial endpoint.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: all-cause mortalityblood pressure controlcardiovascular mortalityhypertensionSPRINT trial
Previous Post

Bronchodilators do not improve symptomatic tobacco-exposure in patients with preserved lung function

Next Post

Percutaneous coronary intervention inefficacious in improving severe ischemic left ventricular dysfunction

RelatedReports

Increased number of daily steps linked with decreased mortality in older women
Lifestyle

Socioeconomic status may influence the association between physical activity and health outcomes

March 10, 2023
Adolescents’ muscle strength associated with lower cardiometabolic risk
Wellness

Wellness Check: Exercise

March 9, 2023
UTI associated with increased risk of preeclampsia
Cardiology

Ultrasound renal denervation associated with reduced blood pressure in the RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials – A pooled analysis

March 6, 2023
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

Endovascular ultrasound renal denervation associated with lower ambulatory systolic blood pressure in patients with hypertension – The RADIANCE II randomized clinical trial

March 6, 2023
Next Post
Shorter time to angioplasty may improve heart attack outcomes

Percutaneous coronary intervention inefficacious in improving severe ischemic left ventricular dysfunction

Cervical length at term helps predict delivery date

Identification of risk factors for incident cervical insufficiency in nulliparous and parous women

Exercise associated with lower pain ratings

Adding weightlifting exercises may further reduce risk of mortality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stroke may be associated with sleep disturbances in adults
  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options